Prospective analysis of KRAS, BRAF, and PIK3CA mutational status and EGFR copy number in patients (pts) with locally advanced rectal cancer: A translational substudy of a clinical trial (SAKK 41/07) evaluating the effect of neoadjuvant chemoradiation (CRT) with or without panitumumab.

Authors

D. Koeberle

Kantonsspital St. Gallen, St. Gallen, Switzerland

D. Koeberle , S. Bougel , J. Benhattar , F. Bosman , O. Gautschi , H. Sun , G. Bodoky , R. von Moos , D. Helbling

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 Gastrointestinal Cancers Symposium

bookmark_border

Pretreatment and postresection epidermal growth factor receptor (EGFR) pathway mutations in a prospective phase II trial (EXCITE) of preoperative cetuximab-containing chemoradiation (CRT) in locally advanced rectal cancer (LARC).

First Author: Simon Gollins

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer.

First Author: Khairun Izlinda Abdul Jalil

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras unmutated, locally advanced rectal cancer (LARC): Final results of a randomized multicenter phase II trial (SAKK 41/07).

First Author: Daniel Helbling

insert_chart_outlined

Poster

2014 Gastrointestinal Cancers Symposium

bookmark_border

Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer: Analysis of a large international cohort of 5,900 patients.

First Author: Gargi Dan Basu